Alector, Inc. (NASDAQ:ALEC) Receives Consensus Recommendation of "Hold" from Brokerages
Alector, Inc. (NASDAQ:ALEC) has received a consensus "Hold" rating from eight brokerages, with an average 12-month price target of $3.625 against a current share price of $2.15. Despite beating quarterly earnings expectations with a smaller loss and higher revenue, the company remains deeply unprofitable, with analysts forecasting continued losses. Insider selling and institutional investment adjustments were also noted.
Industry Analysts Just Upgraded Their Alector, Inc. (NASDAQ:ALEC) Revenue Forecasts By 60%
Analysts have significantly upgraded their near-term revenue forecasts for Alector, Inc. by 60%, pushing the consensus for 2026 revenues to US$11m, despite an expected 21% reduction in sales over the past 12 months. While losses per share are still expected, analysts reduced their loss estimates, indicating increased optimism. The stock has already seen a 36% increase, and it remains to be seen if this upgrade will further propel its value.
Industry Analysts Just Upgraded Their Alector, Inc. (NASDAQ:ALEC) Revenue Forecasts By 60%
Analysts have significantly upgraded Alector, Inc.'s near-term revenue forecasts by 60%, with the consensus for 2026 now standing at US$11 million, despite an expected 21% reduction in sales over the past year. While losses per share are predicted to decrease by 19% to US$0.86, analysts anticipate Alector's revenue decline to accelerate faster than the wider industry. This positive sentiment from the revenue upgrade has coincided with a 36% rise in Alector's stock price over the past week.
HC Wainwright Issues Negative Outlook for Alector Earnings
HC Wainwright has lowered its Q3 and full-year 2026 earnings estimates for Alector, forecasting a deeper loss per share despite the company beating revenue expectations in its latest quarterly results. Alector's stock opened down 5.1% at $1.69, and analysts currently hold a consensus "Hold" rating with an average price target of $3.62. Institutional investors own a significant 85.83% of the shares, while recent insider activity shows sales by the CEO and CFO.
BofA Securities Maintains Alector(ALEC.US) With Sell Rating, Announces Target Price $1
BofA Securities has reiterated its Sell rating for Alector (ALEC.US) and set a target price of $1.00. This analyst action reflects a continued bearish outlook on the company's stock by the firm.
Analysts Offer Insights on Healthcare Companies: Alector (ALEC), Genmab (GMAB) and Xenon (XENE)
Analysts have provided insights on several healthcare companies, including Alector (ALEC), Genmab (GMAB), and Xenon (XENE). Alector received a Hold rating from William Blair, with a consensus Hold rating and a significant upside potential. Genmab was rated Buy by TD Cowen and TipRanks – PerPlexity, maintaining a Strong Buy consensus with a solid upside. Xenon also received a Buy rating from TD Cowen and TipRanks – DeepSeek, leading to a Strong Buy consensus among analysts.
Analysts Offer Insights on Healthcare Companies: Alector (ALEC), Genmab (GMAB) and Xenon (XENE)
Analysts from William Blair and TD Cowen have provided insights on several healthcare companies. Alector (ALEC) received a Hold rating from Myles Minter of William Blair, with a general analyst consensus also at Hold. Genmab (GMAB) was maintained as a Buy by Yaron Werber from TD Cowen, reflecting a Strong Buy consensus, while Xenon (XENE) also received a maintained Buy rating from Joseph Thome of TD Cowen, with a Strong Buy consensus.
H.C. Wainwright Maintains Alector(ALEC.US) With Buy Rating, Maintains Target Price $5
H.C. Wainwright has reiterated its Buy rating for Alector (ALEC.US) and maintained its target price at $5. This indicates continued confidence from the analyst firm in the company's prospects.
Alector Inc (ALEC) Stock News Today
This article provides current stock news for Alector Inc (ALEC), a biotechnology and medical research company. As of the closing bell on August 7th, ALEC stock was trading at $1.780 USD, down 2.73%. The page indicates that more news regarding earnings, analyst ratings, and key developments will be available soon.
Alector Inc (ALEC) Earnings Forecast: Future EPS & Revenue Growth Estimates
Alector Inc (ALEC) has an earnings forecast score of 6.50, ranking 325 out of 387 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $1.50, with a high of $5.00 and a low of $0.75, predominantly recommending a "Hold" for the stock. The company's expected revenue for the next quarter is $2.41M, and its previous quarter's EPS matched market expectations at -$0.21, with the next quarter's EPS projected at -$0.23.
Alector, Inc. 2Q 2026: Revenue $3.32M, EPS $(0.21) — 10-Q Summary
Alector, Inc. reported its second-quarter 2026 results, showing a revenue of $3.32 million, a 57.8% decline year-over-year, and a net loss of $23 million, an improvement from the $30.5 million loss in the prior year. Diluted EPS improved to $(0.21) from $(0.30) YoY. The company is advancing its pipeline with AL137, while GSK discontinued a collaboration, leading to program wind-downs.
Alector, Inc. (ALEC) Stock Price, News, Quote & History
This page provides comprehensive financial data, news, and analysis for Alector, Inc. (ALEC), a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. It includes real-time stock price information, historical performance, key statistics, analyst ratings, and a company overview detailing its pipeline of investigational treatments. The company's stock closed at $1.83, up 22.82%, with a pre-market price of $1.84.
Alector earnings beat by $0.02, revenue topped estimates
Alector (NASDAQ: ALEC) reported better-than-expected Q2 earnings, with an EPS of $-0.21 against an analyst estimate of $-0.23, and revenue of $3.32M, surpassing the consensus of $2.12M. Despite the positive earnings, the company's stock has seen a -11.43% decline in the last three months, though it is up 27.40% over the past year. InvestingPro notes Alector's financial health as "weak performance".
Alector Reports Second Quarter 2026 Financial Results and Provides Business Update
Alector, Inc. reported its second-quarter 2026 financial results, highlighting $172.8 million in cash, cash equivalents, and investments, projected to fund operations through 2027. The company is advancing its Alector Brain Carrier (ABC) platform, with AL137 for Alzheimer's disease targeting an IND submission in Q1 2027, and continued progress in other neurodegenerative programs like AL064/AL164 for tauopathies and AL050 for Parkinson's disease. Alector's net loss for the quarter was $23.0 million, an improvement from $30.5 million in the same period last year, driven by reduced R&D and G&A expenses.
Alector Inc expected to post a loss of 23 cents a share - Earnings Preview
Alector Inc (ALEC) is projected to report a loss of 23 cents per share. This earnings preview suggests analysts are anticipating a negative financial outcome for the company in its upcoming report.
ALEC|Alector Inc|Price:1.510|Chg%:-0.110
This article provides a detailed financial overview of Alector Inc. (ALEC), including its latest earnings report, key financial indicators like EPS, revenue, net profit, and balance sheet details. It also includes an analyst rating of "HOLD" and answers frequently asked questions regarding the company's financial performance in FY2025.
Alector Inc (0Z2) Q4 2022 Earnings Report - Results, Call & Slides
Alector Inc (0Z2) released its Q4 2022 earnings report, missing both EPS and revenue expectations. The company reported an actual EPS of -€0.55 against a consensus of -€0.40 and actual revenue of €12.52M compared to an expected €26.13M. Alector's next earnings date is estimated for November 10, 2026.
Enterprise value to EBITDA forward of Alector, Inc. – NASDAQ:ALEC
This article provides a financial snapshot for Alector, Inc. (NASDAQ: ALEC), focusing on its enterprise value to EBITDA forward. It details that the market for Alector, Inc. is currently closed with no trades. The content is primarily a data presentation from TradingView, with disclaimers about market and reference data providers.
Alector Inc (0Z2) Q4 2023 Earnings Report - Results, Call & Slides
Alector Inc (0Z2) reported its Q4 2023 earnings, beating both EPS and revenue expectations. The company posted an actual EPS of -€0.42 against a consensus of -€0.67, and actual revenue of €13.17M versus an expected €7.66M, representing a YoY revenue growth of +5.19%. The earnings call took place on February 27, 2024, and the next earnings report is estimated for November 10, 2026.
Alector (ALEC) Expected to Post Quarterly Earnings on Thursday
Alector (ALEC) is scheduled to release its Q2 2026 earnings before market open on Thursday, August 6th, with analysts forecasting a loss of $0.24 per share and revenue of $1.43 million. This follows a Q1 report where the company beat EPS estimates but significantly missed revenue expectations. Despite a consensus "Hold" rating, analysts project full-year losses of approximately $1 per share, and recent insider selling has also been noted.
ALEC|Alector Inc|Price:1.640|Chg%:+0.120
Alector Inc (ALEC) has received an overall TradingKey Stock Score of 5.79/10, indicating stable fundamentals and significant growth potential, although its valuation is considered fairly valued. Institutional ownership is very high, and analysts have recently rated the stock as "Hold" with a target price of $3.10. The company, a clinical-stage biotechnology firm focused on neurodegenerative diseases, is in a growing phase but faces risks such as being overvalued and institutional selling.
Alector Inc (ALEC) Valuation: PE, PB & Fair Value Analysis
This article analyzes the valuation of Alector Inc (ALEC), noting its current valuation score of 6.90 within the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -1.28 and mentions that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed. The analysis provides key financial metrics and a brief overview of Alector Inc's market performance.
Alector Inc (ALEC) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Alector Inc (ALEC), listing major shareholders and their proportional holdings, as well as the types of shareholders. It also provides a historical overview of institutional shareholding, including the number of institutions, shares held, and changes over recent quarters. The report concludes with a list of ETFs related to Alector Inc and their proportional holdings.
Alector Inc (ALEC) Cash Flow Statement
This article provides Alector Inc's (ALEC) cash flow statements, including quarterly and annual data for operating, investing, and financing activities. It also defines these cash flow types and free cash flow, explaining their importance for evaluating a company's financial health, with specific figures for Alector Inc's latest quarter and fiscal year.
Alector Inc (ALEC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Alector Inc (ALEC), noting that relevant data regarding business segments, regional revenue, and profit contribution has not yet been disclosed by the company. It briefly presents the stock’s current trading information, including its market cap and recent price movements. The page serves as a placeholder for detailed financial analysis that is currently unavailable.
ALEC|Alector Inc|Price:1.520|Chg%:+0.040
Alector Inc. (ALEC) is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company's pipeline includes latozinemab and AL101/GSK4527226, targeting progranulin levels, and several preclinical candidates utilizing its ABC blood-brain barrier platform. ALEC's stock information, executive team, and institutional ownership details are provided, showing a market cap of 168.76M.
ALEC|Alector Inc|Price:1.480|Chg%:-0.010
Alector Inc (ALEC) is a clinical-stage biotechnology company focused on neurodegenerative diseases. The stock is currently trading at $1.480, down 0.67%, with a market capitalization of $164.32 million. Analysts rate the stock as "Hold" with a target price of $3.10, suggesting a potential upside of 108.05%.
Spruce Street Capital LP Buys 983,082 Shares of Alector, Inc. $ALEC
Spruce Street Capital LP significantly increased its stake in Alector, Inc. (NASDAQ:ALEC) by 87.9% in the first quarter, purchasing an additional 983,082 shares to bring its total holding to over 2.1 million shares, representing about 1.89% of the company. Alector's stock recently traded down 0.7% to $1.48, well below its 52-week high, despite beating EPS expectations but falling short on revenue. Analysts currently maintain a consensus "Hold" rating with an average price target of $3.62 for the clinical-stage biotechnology company.
Alector, Inc. Revenue Breakdown – NASDAQ:ALEC
Alector, Inc. (NASDAQ:ALEC) generated $21.05 million USD in revenue last year, primarily from its Immuno-neurology segment. This figure is a decrease from the previous year's $100.56 million USD. The United States was the company's largest contributor to revenue.
Alector, Inc. (NASDAQ:ALEC) Receives Average Recommendation of "Hold" from Analysts
Alector, Inc. (NASDAQ:ALEC) has an average analyst rating of "Hold" based on eight analysts, with a target price of $3.63. Recent insider selling by the CFO and CEO totaled 115,760 shares, and the stock is trading near its 52-week low. Despite reporting a smaller-than-expected quarterly loss, the company's revenue significantly missed analyst estimates.
Alector (ALEC) Proxy filing Summary
Alector (ALEC) has announced its annual meeting for June 17, 2026, to be held virtually. Key proposals include the election of three directors, the ratification of Ernst & Young, LLP as the independent accounting firm, and an advisory vote on executive compensation, all recommended for approval by the Board. The company's proxy materials are available online, and the Board of Directors includes individuals with medical and scientific backgrounds.
Alector (ALEC) Goldman Sachs 45th Annual Global Healthcare Conference Summary
This article summarizes Alector's presentation at the Goldman Sachs 45th Annual Global Healthcare Conference, highlighting its strategic focus on eradicating neurodegenerative diseases by leveraging human genetics, immunology, and neuroscience. The company's clinical pipeline includes late-stage programs for Alzheimer's and frontotemporal dementia, with key upcoming milestones such as data readouts for AL002 and latozinemab expected by year-end and 2025, respectively. Alector aims to file at least one new IND annually and is integrating blood-brain barrier technology to enhance drug delivery.
Alector (ALEC) Proxy filing Summary
Alector (ALEC) has filed a proxy summary detailing its virtual annual meeting scheduled for June 17, 2026. Shareholders will vote on electing three Class II directors, ratifying Ernst & Young LLP as auditor, and an advisory say-on-pay for executive compensation. The board recommends voting for all proposals and has set the record date for voting as April 20, 2026, with over 111 million shares outstanding.
GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership
GSK's licensor Hansoh Pharmaceutical announced positive Phase 3 data for risvutatug rezetecan (Ris-Rez) in advanced or relapsed small-cell lung cancer, demonstrating improved overall survival. This marks the first positive Phase 3 survival data for a B7-H3-targeted antibody-drug conjugate. Concurrently, GSK terminated its collaboration agreement with Alector due to failed trials for their investigational progranulin-elevating monoclonal antibodies.
GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership
GSK's licensor Hansoh Pharmaceutical Group announced positive Phase 3 trial results for risvutatug rezetecan (Ris-Rez) in advanced small-cell lung cancer, showing significant improvements in overall survival. This marks the first positive Phase 3 survival data for a B7-H3-targeted antibody-drug conjugate. Additionally, GSK has terminated its collaboration with Alector Inc. after two investigational treatments for neurodegenerative diseases failed to meet their endpoints in clinical trials.
Form 4 Alector Inc For: 9 July By Investing.com
This article announces the filing of a Form 4 by Alector Inc. on July 9th, as reported by Investing.com. It is a brief news item indicating insider transaction activity for the company Alector (ALEC). The article also lists various market data like indices, commodities, and stock performances.
Alector and GSK partnership to end after dementia, Alzheimer's drug failures
Alector announced GSK is terminating their neuroscience collaboration agreement after two experimental antibody drugs for frontotemporal dementia and Alzheimer's disease failed in clinical trials. This decision follows setbacks for latozinemab in a late-stage study and nivisnebart in a mid-stage trial, leading to significant workforce reductions at Alector. The termination for the deal, which initially saw Alector receive $700 million upfront, will become effective in January next year.
Form 4 Alector Inc For: 9 July By Investing.com
This article announces a Form 4 filing for Alector Inc. on July 9th. It is a brief financial news item from Investing.com, providing a simple update on the company's regulatory filings. The article also includes various market data and related news not directly tied to the Alector Inc. filing.
Alector (ALEC) awards 20,000 RSUs to principal accounting officer
Alector, Inc. (ALEC) has awarded 20,000 Restricted Stock Units (RSUs) to its Principal Accounting Officer, Grace Wong-Sarad. These RSUs will vest in 12 equal quarterly installments starting September 1, 2026, and after this grant, Wong-Sarad holds 115,461 shares of common stock. This award is intended to align her compensation with the company's long-term performance.
GSK ends Alector alliance as both lead assets fail
GSK has terminated its five-year neuroscience collaboration with Alector after two experimental antibody drugs, latozinemab and nivisnebart, failed in clinical trials for frontotemporal dementia and Alzheimer's disease, respectively. While GSK exits the partnership, it continues to pursue external innovation, as evidenced by its recent acquisition of Nuvalent and expanded alliances with Wave Life Sciences and Flagship Pioneering. This termination is Alector's second major partnership loss in 18 months, though the company still retains three wholly-owned clinical candidates, including an anti-amyloid antibody, showing potential for its longer-term pipeline.
Alector (ALEC) Shares Drop 13% Following Termination of GSK Collaboration
Alector Inc. (ALEC) shares dropped 13% after GSK terminated their collaboration on two experimental antibody drugs due to clinical trial failures, including latozinemab for frontotemporal dementia and nivisnebart for Alzheimer's. This setback highlights significant challenges for Alector, given its low GF Score of 30, indicating weaknesses in financial strength and profitability, and recent insider share sales. The termination, effective in 180 days, comes despite Alector having received substantial payments from the 2021 deal.
Alector stock plummets 13% as GSK terminates neuroscience pact (GSK:NYSE)
Alector's stock plunged 13% after GSK terminated their neuroscience collaboration due to clinical setbacks with two experimental antibody drugs. GSK's shares eased by 1.5% following the announcement. This decision highlights the risks associated with pharmaceutical drug development partnerships.
Alector and GSK partnership to end after dementia, Alzheimer's drug failures
Alector announced that GSK has terminated their neuroscience collaboration agreement for two experimental antibody drugs following clinical setbacks. This decision comes after the failure of a late-stage study for latozinemab in frontotemporal dementia and the discontinuation of a mid-stage Alzheimer's trial for nivisnebart, leading to Alector cutting nearly half its workforce. The termination will become effective on January 2 next year.
Alector (ALEC) sees GSK end antibody collaboration while repaying $10.4M loan
Alector (ALEC) announced that GSK has terminated their 2021 collaboration and license agreement for progranulin-elevating antibodies latozinemab and nivisnebart, effective January 2, 2027. This decision follows the discontinuation of Phase 3 and Phase 2 trials for these programs due to not meeting clinical goals. Concurrently, Alector fully repaid a $10.4 million loan to Hercules Capital, including accrued interest and charges.
Alector to End GSK Progranulin Collaboration; Repays $10.4 Million Hercules Loan
Alector announced the termination of its collaboration and license agreement with GSK for progranulin-elevating antibodies, effective January 2, 2027, following clinical trial setbacks. Concurrently, Alector repaid a $10.4 million loan to Hercules Capital, including principal, interest, and various charges, on July 8, 2026. These actions aim to streamline the company's operations by ending the GSK alliance and eliminating outstanding debt.
Alector (ALEC) BofA Securities 2025 Healthcare Conference Summary
Alector has refined its pipeline focus, prioritizing CB-010 for lymphoma and CB-011 for myeloma, to extend its cash runway into the second half of 2027. Both programs show promising early efficacy and are designed as off-the-shelf cell therapies. The company is strategically advancing these assets to critical inflection points with ongoing discussions with the FDA regarding trial designs, while leveraging outsourced manufacturing for flexibility.
0Z2 Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Alector, Inc. (0Z2) stock, based on analyst opinions. It includes financial data such as past earnings, revenue, net income, and EBITDA, along with important dates like the next earnings report. The piece also answers frequently asked questions about the company's stock dynamics, employee count, and how to trade its shares.
Alector, Inc. Actuals & Estimates (NASDAQ:ALEC)
This article provides an overview of Alector, Inc. (NASDAQ:ALEC) stock performance, financial estimates, and analyst forecasts. It covers metrics such as current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings dates. The information is presented in a Q&A format, detailing various financial aspects and investment considerations for ALEC.
ALEC Forecast — Price Target — Prediction for 2027
This article provides a forecast, price target, and prediction for Alector, Inc. (ALEC) stock for 2027, based on analyst opinions and financial data. It covers current stock price, historical performance, earnings reports, market capitalization, and volatility, along with a disclaimer that the information is not investment advice.
Enterprise value to EBIT forward of Alector, Inc. – NASDAQ:ALEC
The article displays the enterprise value to EBIT forward for Alector, Inc. (NASDAQ: ALEC). It appears to be a financial data snippet from a larger platform, possibly TradingView, focusing solely on this specific financial metric for the given company.
